Latest Conference Articles
Stay up to date on the latest oncology and nursing conferences.
Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment
June 9th 2021, 2:00pm
Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.
Second-Generation CAR T-Cell Therapy Is ‘Highly Promising’ in Relapsed/Refractory B-NHL
June 8th 2021, 6:30pm
The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Sacituzumab Govitecan Beats All Chemo Regimens in TNBC Treatment
June 8th 2021, 1:31pm
Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.
Acalabrutinib: Same Survival Rates, But Better Tolerated Than Ibrutinib in CLL Treatment
June 7th 2021, 5:51pm
Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.
Melanoma Outcomes Are Improved With Nivolumab Alone or With Ipilimumab
June 7th 2021, 1:56pm
Nivolumab with or without ipilimumab improved survival over ipilimumab alone in patients with previously untreated advanced melanoma.
Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer
June 6th 2021, 7:00pm
Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.
Adjuvant Chemo Does Not Improve Survival in Locally Advanced Cervical Cancer
June 5th 2021, 3:30pm
Adjuvant carboplatin and paclitaxel after standard cisplatin-based chemoradiation did not demonstrate improved overall survival or progression-free survival in patients with locally advanced cervical cancer.
Pralsetinib Is Tolerable, Durable in RET Fusion+ NSCLC
June 4th 2021, 5:21pm
Pralsetinib elicited promising responses and tolerability in patients with RET fusion-positive non-small cell lung cancer (NSCLC), including those who were not eligible for platinum-based therapy.
Olaparib Is Beneficial 1 Year After Standard of Care Therapies in BRCA, High-Risk, Early HER2- Breast Cancer
June 4th 2021, 2:16pm
Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.
Restrictive Medicaid Eligibility May Negatively Impact Cancer Survival
May 21st 2021, 1:20pm
States without Medicaid expansion tended to have poorer cancer outcomes than states with higher income limits on eligibility, according to recent research.